Loading clinical trials...
Loading clinical trials...
Effect of Fetal Aortic Valvuloplasty on Outcomes. A Prospective Observational Cohort Study With a Comparison Cohort
In one of the most severe congenital heart defects, hypoplastic left heart syndrome (HLHS), the left ventricle is underdeveloped and the prognosis is worse than in most other heart defects. The underdevelopment can occur gradually during fetal growth caused by a narrowing of the aortic valve. At some international centers, such fetuses are treated with a balloon dilation of the narrowed valve, but there is no scientifically sound evidence that this treatment is effective. The aim of this study is: 1/ to evaluate whether balloon dilation during the fetal period of a narrowed aortic valve can reduce the risk of the left ventricle becoming underdeveloped and the baby being born with a so-called univentricular heart (HLHS); 2/ to investigate whether such treatment improves the prognosis for this group of children with a very complex and severe heart defect and 3/ to also describe side effects and risks in fetuses and mothers of the fetal procedure.
Routinely collected pre- and postnatal clinical data will be entered into a digital database and echocardiographic examinations will be uploaded to a server. A core lab will measure and analyze all echocardiographic examinations according to protocol. The growth of the left heart structures and the postnatal outcome will be compared between the intervention and non-intervention groups. The decision whether a fetal balloon dilatation shall be attempted is not part of the study protocol. The number of examinations of mother/fetus/infant in this study is not different from the number of examinations that will be recommended for someone choosing not to be part of this study. Participation in the study does not affect the care and treatment mothers and fetuses are receiving during pregnancy, nor how the infant is examined and treated after birth.
Age
0 - 0 years
Sex
ALL
Healthy Volunteers
No
Fetal Cardiovascular Program, University of California San Francisco
San Francisco, California, United States
Congenital Heart Collaborative, Nationwide Children's Hospital
Columbus, Ohio, United States
Kinderherzzentrum Linz
Linz, Austria
The Hospital for Sick Children Toronto
Toronto, Canada
Department of Paediatric Cardiology, Helsinki University Children's Hospital
Helsinki, Finland
Pediatric Cardiology - University Hospital Bonn
Bonn, Germany
Department of Pediatric and Congenital Cardiology, University of Heidelberg
Heidelberg, Germany
University hospital Technical university, mother- and-child center
Munich, Germany
Department of Perinatal Cardiology and Congenital Anomalies, Centre of Postgraduate Medical Education.
Warsaw, Poland
Fetal Medicine Unit, Dept. Obstetrics & Gynecology University Hospital 12 de Octubre
Madrid, Spain
Start Date
January 1, 2021
Primary Completion Date
December 31, 2029
Completion Date
December 31, 2029
Last Updated
March 21, 2025
200
ESTIMATED participants
Fetal aortic balloon dilatation
PROCEDURE
Lead Sponsor
Queen Silvia Children's Hospital, Gothenburg, Sweden
Collaborators
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and ConditionsNCT07042334